Standing Ovation secures €30 million in Series B funding.

      The precision fermentation startup based in Paris has successfully validated industrial-scale production of its Advanced Casein in collaboration with Bel Group. The proceeds from the Series B funding will support its commercial launch in the US in 2026, with expansions into Europe and Asia anticipated by the end of 2027, subject to regulatory approvals.

      Standing Ovation, the Parisian startup creating casein from dairy waste, has secured €30 million ($34.2 million) in a Series B funding round. This round includes €25 million in equity, co-led by the Ecotechnologies 2 fund, managed by Bpifrance as part of France's France 2030 initiative, and Crédit Mutuel Innovation, along with existing investors such as Astanor, Bel Group, Seventure Partners, GoodStartUp, and Big Idea Ventures. Three new investors, Danone Ventures, Angelor, and Newtree, have also joined. Additionally, there was €5 million in non-dilutive funding from Bpifrance and a banking syndicate. This financing follows a €16 million Series A round, bringing total funding so far to approximately €46 million.

      Co-founded in 2020 by Romain Chayot, a microbiologist and agronomist serving as Chief Scientific Officer, the company is currently led by CEO Yvan Chardonnens. Its main product, Advanced Casein, is a protein derived not from cows but through the precision fermentation of dairy by-products, mainly acid whey from cheese manufacturing.

      The importance of this molecule cannot be overstated: casein comprises about 80% of milk's protein content and contributes to the melt, stretch, and creaminess that make dairy products essential for formulation. While much of the precision fermentation industry has concentrated on whey proteins, which are technically easier to produce, Standing Ovation is focusing on casein, which is significantly more challenging but offers greater value.

      Industrial validation took place last October when Standing Ovation and Bel Group, a cheese giant known for La Vache Qui Rit and a strategic partner since 2022, announced the first industrial-scale production of precision fermentation-derived casein utilizing Bel’s acid whey as a feedstock. An independent and certified life cycle assessment found that this process achieves a 74% reduction in CO₂ emissions, a 99% reduction in land use, and a 68% decrease in water consumption compared to traditional animal-derived casein.

      Standing Ovation describes its product as a “drop-in” ingredient that is functionally, nutritionally, and organoleptically identical to conventional casein, allowing food manufacturers to maintain existing recipes without reformulation. The Series B funding will facilitate its commercial rollout, targeting the US market for a 2026 launch, pending certified GRAS (Generally Recognized as Safe) regulatory approval—a more stringent path than the self-affirmation used by some competitors. In Europe and Asia, the launch is scheduled for late 2027, also depending on regulatory approvals in those regions.

      The company is adopting an asset-light manufacturing strategy by collaborating with established fermentation manufacturers instead of constructing its own facilities, which will help speed up market entry. The partnership with Bel Group provides Standing Ovation with a reliable source of feedstock and a significant industry endorsement; the addition of Danone Ventures as an investor marks another notable dairy industry player backing the company in a sector where established companies have strong motivations to control the market entry of fermentation-derived alternatives.